



10 July 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

U.S. Subsidiary Change of Name

Hemogenyx Pharmaceuticals plc is pleased to announce that its U.S. subsidiary will be renamed Hemogenyx Pharmaceuticals LLC in order to align the Company's names across entities and countries, and should always be referred to as Hemogenyx Pharmaceuticals instead of Hemogenyx by itself. The company will continue to conduct preclinical and clinical stage research and development activities to develop its own products and therapies, including therapies and treatments for blood and autoimmune diseases and viral infections. Hemogenyx Pharmaceuticals LLC will remain located at its state-of-the-art research facility in New York City.

Enquiries:

Hemogenyx Pharmaceuticals plc

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Peter Redmond, Director

<https://hemogenyx.com>

headquarters@hemogenyx.com

SP Angel Corporate Finance LLP

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Tel: +44 (0)20 3470 0470

Peterhouse Capital Limited

Lucy Williams, Duncan Vasey, Charles Goodfellow

Tel: +44 (0)20 7469 0930

US Media enquiries

Lowell Goodman

Tel: +1 (323) 646-3249

lowell@corbomitecomms.com